Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Queen Mary University of London and OCDEM researchers develop alternative treatment for patients as young as three months.

Photo of baby feet

In a new study, published in the journal NEJM, scientists including Professor Rajesh Thakker, have developed a new way to treat patients with low blood calcium values and recurrent seizures caused by a genetic condition known as autosomal dominant hypocalcaemia type 1(ADH1). This condition reduces secretion of parathyroid hormone (PTH) and also increases urine calcium excretion.

The study used subcutaneous PTH infusions delivered by a portable pump (approx 6x3x1 cm), that is usually used for insulin treatment in patients with diabetes mellitus, in patients with ADH1 for whom conventional treatment with tablets of a drug called alpha-calcidol was insufficient.

The PTH infusion stopped seizures in all patients, reduced hospital admissions, and also increased calcium concentrations, without increasing urine calcium excretion. Treatment was given to a total of 6 patients, of which 4 were below 1 years old and 3 were below 3 months old, and has continued for an average of 3.5 years for the duration of the study.

Dr Evelien Gevers, Clinical Reader at The Centre of Endocrinology, Queen Mary University of London and Consultant Paediatric Endocrinologist at Royal London Children’s Hospital (part of Barts Health NHS Trust), said: “Our findings are important as all patients that started below 1 years old had normal developmental milestones. PTH treatment using portable insulin pumps is feasible even over many years and in small babies, and is a more physiological treatment for ADH1 and also for other forms of hypoparathyroidism, at least until other treatment options are available.”

Read the paper. 

Similar stories

£520,000 grant to test treatment for haemophilia-related ankle arthritis

Dr Nikki Curry from the Radcliffe Department of Medicine, and Steph Taylor from the Oxford Haemophilia & Thrombosis Centre, have been awarded a clinical trial grant from the National Institute of Health and Care Research for Patient Benefit (NIHR RfPB) funding stream to improve treatment for the ankle arthritis caused by haemophilia.

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.

Similar stories

£520,000 grant to test treatment for haemophilia-related ankle arthritis

Dr Nikki Curry from the Radcliffe Department of Medicine, and Steph Taylor from the Oxford Haemophilia & Thrombosis Centre, have been awarded a clinical trial grant from the National Institute of Health and Care Research for Patient Benefit (NIHR RfPB) funding stream to improve treatment for the ankle arthritis caused by haemophilia.

Researchers highlight need for better sleep support for NHS shift workers

A new study led by researchers at the University of Oxford’s Radcliffe Department of Medicine, has found that many NHS staff working shifts experience sleep difficulties, with researchers calling for more accessible, evidence-based support to help staff manage sleep.

Oxford spin-out raises $90 million to advance new treatments for blood cancers

Alethio Therapeutics, a University of Oxford spin-out co-founded by Professors Adam Mead and Beth Psaila, has secured $90 million (£67 million) in oversubscribed Series A financing to develop a new generation of therapies for myeloproliferative neoplasms (MPNs).

Breakthrough in non-invasive liver testing

Two major international studies, including an imaging study led by researchers from the Radcliffe Department of Medicine, have provided new evidence on which non-invasive tests can accurately diagnose and measure the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, potentially reducing reliance on liver biopsy.

Oxford-led research identifies a new therapeutic strategy to reverse established atrial fibrosis in atrial fibrillation

Researchers at the University of Oxford have identified a promising new RNA-based therapeutic approach that can reverse established atrial fibrosis. Atrial fibrosis is a major contributor to atrial fibrillation, the most common sustained cardiac arrhythmia worldwide.

Therapy Acceleration Lab achieves Medical Laboratory Accreditation

The Therapy Acceleration Lab (TAL) at the MRC WIMM has been accredited by the United Kingdom Accreditation Service (UKAS) to ISO 15189:2022 – Medical laboratories – Requirements for quality and competence.